Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 301

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 301
---
 842 for short-term leases (less than 12 months) whereby a lease liability and right of use asset will
not be recorded for short-term leases.

| 5. | In 2019, a disagreement                                                                                                                 
 has arisen between the Company and CSL Behring GmbH, or CSL, whether certain unshipped minimum purchase commitments for fibrinogen      
 from 2018 to 2020 are to be paid by the Company pursuant to a Framework Supply Agreement dated March 8, 2016, or Framework Supply       
 Agreement, by and between the Company and CSL, whereby CSL agreed to supply the Company with fibrinogen. On January 14, 2020, the       
 Company received a termination letter, or CSL Termination Letter. In the CSL Termination Letter, CSL demanded a total amount of $820,   
 claiming it was owed the minimum purchase commitment amounts under the Framework Supply Agreement not paid by the Company in 2018       
 and 2019. In a subsequent correspondence, CSL additionally demanded interest and damages for lost profit, with an aggregate demand      
 amount of $1,476. The Company has disputed CSL’s payment demand and contends that CSL’s demands are baseless under the                  
 Framework Supply Agreement, as the minimum purchase commitment under the Framework Supply Agreement is conditional upon first obtaining 
 approval of the FDA and the European Medicines Evaluation Agency, or EMEA, and other quality and clinical milestones, none of which     
 has occurred. Notwithstanding, CSL claimed to have obtained a valid German court order in its favor and to endeavor to seek for its     
 enforcement in Israel. Company’s position is that CSL’s claim for the payment of the said unshipped minimum purchase                    
 commitments lacks any ground under the terms of the Framework Supply Agreement and, moreover, that the Company was never served with    
 German judicial documents (e.g., statement of claim) of CSL with translations in Hebrew, English or Arabic, as required under the       
 applicable German and international rules of proceeding. Consequently, based on advice of a German legal counsel, the Company are       
 in the opinion that the legal proceeding initiated by CSL suffered a fundamental and material procedural error and that no enforceable  
 German judgement could derive thereto. In 2024, the Company has initiated a proceeding in Germany to annul said German court’s          
 purported ruling. A hearing to annul the judgement in Germany was scheduled for April 2025 and a hearing to discuss the enforcement     
 in Israel was scheduled for June 2025. With respect to the hearing to